CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses ...

Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Here are 10 new shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Editor’s note: The drugs listed are in ...

Kura Oncology, Inc. (Nasdaq: KURA, "Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin”) today announced that an a ...

Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial HypertensionBOSTON and ATLANTA, May 14, 2025 ...

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

Please provide your email address to receive an email when new articles are posted on . Imatinib interruption resulted in shorter median OS. Interruption also appeared linked to rapid progression ...

Department of Sarcoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Although it is well known that interruption of imatinib leads ...

Please note - this trial is no longer recruiting patients. We hope to add results when they are available. This trial is for people with gastrointestinal stromal tumour (GIST) who have had surgery and ...